家庭与门诊肺量计监测哮喘肺功能的一致性比较
该事后分析基于CAPTAIN(2436例)和205832(421例)两项随机试验,比较未控制哮喘患者家庭与门诊谷值FEV1测量的一致性。结果显示家庭肺量计测得的FEV1改善幅度更低且不一致,Bland-Altman图提示两者一致性差,家庭读数不可替代门诊测量。
要点
- 家庭肺量计与门诊肺量计测得的谷值FEV1一致性差,不可互换。
- 家庭肺量计测得的FEV1改善幅度低于门诊测量且一致性更差。
- 结果仅适用于研究中使用的特定设备与指导方法。
核心结论
- 在未控制哮喘患者中,家庭肺量计测得的谷值FEV1与门诊测量一致性差,家庭读数不可替代门诊测量。
研究设计与样本
- 事后分析,使用CAPTAIN(205715;NCT02924688)和205832(NCT03012061)两项随机双盲平行组试验的谷值FEV1数据。
- CAPTAIN trial纳入2436例患者,205832 trial纳入421例患者。
- 通过家庭肺量计和门诊监督下肺量计收集谷值FEV1,采用时间进程分析和Bland-Altman图评估一致性。
主要发现
- 两项试验中,家庭和门诊肺量计均观察到治疗相关的FEV1改善。
- 家庭肺量计测得的改善幅度低于门诊测量,且一致性更差。
- Bland-Altman图提示基线和第24周家庭与门诊谷值FEV1一致性差。
临床怎么用
- 临床解读家庭肺量计FEV1结果时应谨慎,不应直接等同于门诊肺量计测量值。
- 家庭肺量计监测需结合特定设备与指导方法,其结果可能不适用于其他场景。
局限性
- 结果为事后分析,可能受原试验设计限制。
- 结论仅适用于研究中使用的特定家庭肺量计设备与指导方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Studies examining agreement between home and clinic spirometry in patients with asthma are limited, with conflicting results. Understanding the strengths and limitations of telehealth and home spirometry is particularly important considering the SARS-CoV-2 pandemic. RESEARCH QUESTION: How well do home and clinic measurements of trough FEV1 agree in patients with uncontrolled asthma? STUDY DESIGN AND METHODS: This post hoc analysis used trough FEV1 data from the randomized double-anonymized parallel-group phase 3A CAPTAIN (205715; NCT02924688) and phase 2B 205832 (NCT03012061) trials in patients with uncontrolled asthma. CAPTAIN evaluated the impact of adding umeclidinium to fluticasone furoate/vilanterol via a single inhaler; the 205832 trial investigated adding umeclidinium to fluticasone furoate vs placebo. Trough FEV1 measurements were collected via home spirometry and supervised in-person spirometry in the research clinic. To compare home and clinic spirometry, we examined the time-course analyses of home and clinic trough FEV1, and generated post hoc Bland-Altman plots to assess agreement between home and clinic spirometry. RESULTS: Data from 2,436 patients (CAPTAIN trial) and 421 patients (205832 trial) were analyzed. Treatment-related improvements in FEV1 were observed in both trials, using home and clinic spirometry. Improvements measured by home spirometry were of lower magnitude and less consistent than clinic measurements. Bland-Altman plots suggested poor agreement between home and clinic trough FEV1 at baseline and week 24. INTERPRETATION: This post hoc comparison of home and clinic spirometry is the largest conducted in asthma. Results showed that home spirometry was less consistent than and lacked agreement with clinic spirometry, suggesting that unsupervised home readings are not interchangeable with clinic measurements. However, these findings may only be applicable to home spirometry using the specific device and coaching methods employed in these studies. Postpandemic, further research to optimize home spirometry use is needed. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; Nos.: NCT03012061 and NCT02924688; URL: www. CLINICALTRIALS: gov.
引用
- Oppenheimer J, Hanania NA, Chaudhuri R, et al. Clinic vs Home Spirometry for Monitoring Lung Function in Patients With Asthma. Chest. 2023. PMID: 37385337. doi:10.1016/j.chest.2023.06.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。